Abstract
The development, progression, or stabilization of the atherosclerotic plaque depends on the pro-inflammatory and anti-inflammatory macrophages. The influx of the macrophages and the regulation of macrophage phenotype, inflammatory or anti-inflammatory, are controlled by the small GTPase RhoA and its downstream effectors. Therefore, macrophages and the components of the RhoA pathway are attractive targets for anti-atherosclerotic therapies, which would inhibit macrophage influx and inflammatory phenotype, maintain an anti-inflammatory environment, and promote tissue remodeling and repair. Here, we discuss the recent findings on the role of macrophages and RhoA pathway in the atherosclerotic plaque formation and resolution and the novel therapeutic approaches.
Original language | English (US) |
---|---|
Article number | 216 |
Pages (from-to) | 1-13 |
Number of pages | 13 |
Journal | International journal of molecular sciences |
Volume | 22 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2021 |
Keywords
- Atherosclerosis
- Foam cells
- Inflammation
- Macrophages
- RhoA
- Plaque, Atherosclerotic/immunology
- Humans
- Lipid Metabolism
- Arteries/metabolism
- Atherosclerosis/immunology
- Foam Cells/enzymology
- Animals
- rhoA GTP-Binding Protein/metabolism
ASJC Scopus subject areas
- Catalysis
- Molecular Biology
- Spectroscopy
- Computer Science Applications
- Physical and Theoretical Chemistry
- Organic Chemistry
- Inorganic Chemistry